FDA Approves JIDEYTRO — Nuvalent, Inc.

Nuvalent, Inc. received FDA approval for the oral kinase inhibitor JIDEYTRO (zidesamtinib), clearing the path for its commercial launch later this year and marking a significant expansion of the oncologist toolkit for treating EGFR 20 insertion NSCLC. The approval is expected to reinforce Nuvalent's competitive positioning in the rapidly growing targeted oncology market and drive potential revenue growth against rivals like AbbVie.